“Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis”, J of Skin, vol. 2, no. S1, p. S22, Feb. 2018, doi: 10.25251/skin.2.supp.22.